Federal Health Grants

The Innovation in Behavioral Health (IBH) Model (the Model) is an eight-year, voluntary service delivery and payment model promoting integrated care in behavioral health (BH) settings. The IBH Model will test the impact of a value-based payment (VBP) model aligned across Medicaid and Medicare that supports an integrated care delivery framework in specialty BH organizations and settings for adult Medicaid, Medicare, and dually eligible beneficiaries with moderate to severe mental health conditions and/or substance use disorders (SUDs).The Centers for Medicare Medicaid Services (CMS), through its Center for Medicare Medicaid Innovation (Innovation Center), will select up to eight state Medicaid agencies (SMAs) to participate in the Model. Implementation will begin in January 2025 and end in December 2032. The Model will have an eight-year performance period, which will be comprised of a three-year Pre-Implementation Period along with a five-year Implementation Period. Up to $7.5 million dollars in cooperative agreement award funding will be available to each selected Recipient over the course of the eight years.

This funding opportunity supports researchers investigating new and existing risk factors for liver cancer, focusing on population-based studies to improve understanding and prevention of the disease in the U.S.

This funding opportunity provides substantial financial support to state and local public health agencies to modernize their operations, expand their workforce, and improve data systems, ultimately enhancing public health services and addressing health disparities.

The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s).Funding Opportunity Description Introduction The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), is transforming the translational science process so that new treatments and cures for disease can be delivered to patients faster. NCATS strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline in an effort to speed the delivery of new drugs, diagnostics and medical devices to patients. This funding opportunity announcement (FOA) aims to promote innovative research to increase knowledge of understudied proteins associated with rare diseases. The submission of small research grant (R03) applications is encouraged from institutions and organizations proposing projects leading to a better understanding of eligible proteins listed below. Small research (R03) grants provide flexibility for initiating discrete, well-defined projects that realistically can be completed in one year and require only limited levels of funding. This program supports different types of projects including, but not limited to, the following: Pilot or feasibility studies; Small, self-contained research projects; Development of research methodology; and/or Development of assays to support compound screening projects; Development of human cell or animal based models. These awards will support generation of preliminary data and tools around eligible understudied protein(s) with the intent of elucidating the function of these proteins in the context of rare disease and obtaining sufficient preliminary data and/or research resources for subsequent grant applications and/or drug discovery projects. These grants are non-renewable. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Background The human genome has revealed a great deal about the human proteome, though significant portions of the genome remain understudied. Only a subset of expressed proteins demonstrates the requisite properties to serve as targets for the development of therapeutics. Many bona fide drug targets likely remain to be studied in the Druggable Proteome (DP), which can be defined as the fraction of proteins which have the ability to bind drug-like molecules. The term "drug-like" refers to the physical, biochemical, and pharmacological attributes of small molecule compounds that are generally recognized to be required for efficacious clinical drugs in humans. While the number of proteins in the DP is upwards of 4,500, the existing clinical pharmacopeia is represented by only a few hundred targets, leaving a huge swath of druggable biology unexploited. The expanded exploration of the relationship between the protein and the rare disease phenotype, or the development of a useful tool or reagent can accelerate research into a previously understudied protein. Many interesting and critical biological processes and potential therapeutic avenues remain unexplored because an initial catalyzing event (e.g., association with a biologic process or phenotype, creation of tools or reagents for the protein, etc.) has not yet occurred. The purpose of this FOA is to spark such catalyzing events through the support of small R03 awards to identify novel drug targets for the treatment of human disease, specifically rare disease Objectives and Scope The goal of this specific solicitation is to provide a needed opportunity for the collection of preliminary data around the role of understudied proteins associated with rare diseases. This FOA will provide funding to support research that will characterize new targets for treatment of human disease among the understudied proteins of the Druggable Proteome. These projects should be carried out in a short period of time with limited resources as defined by the funding mechanism. It has been recognized through workshops and publications that understudied proteins become illuminated when (1) there are tools to study the protein (e.g., tools that modulate protein activity) and/or (2) there is biochemical, cellular, or animal model evidence of disease/physiological relevance. This FOA was developed to address the need for expanded research and validation experiments on eligible understudied protein(s), with the intent of producing preliminary data to address the lack of biochemical, cellular, or animal model data associated with many understudied proteins. It is expected that the award will be used to obtain preliminary data and/or research resources for subsequent grant applications and/or drug discovery projects. The NIH supports research on a broad range of diseases that are defined as rare; that is diseases affecting fewer than 200,000 individuals in the United States (per the Rare Disease Act of 2002). Collectively, there are an estimated 7,000 rare diseases, which affect approximately 25-30 million people in the United States. Most are serious or life-threatening, with a disproportionate number of rare diseases affecting children. At this time, effective treatments are available for fewer than 5%. The IDG Program has linked over 6,000 proteins to rare diseases, with over 80% of these proteins considered extremely understudied. For the purposes of this FOA, eligible proteins are those that have an association with rare disease through data mining of the encyclopedia of rare disease annotations for precision medicine (eRAM) and Orphanet, are considered understudied (those proteins that lack small molecule binders and/or have limited biological characterization) and are within a protein family that is traditionally considered druggable.

The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The overarching goal of this UE5 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in computational genomics and data science research. To accomplish the stated over-arching goal, this NOFO will support creative educational activities with a primary focus on: Courses for Skills Development Specifically, this UE5 program will support faculty members at minority-serving institutions (MSIs) to create undergraduate or masters degree courses in computational genomics, data science, or a combination of these topics. Support for this activity will be provided by the Educational Hub for Enhancing Diversity in Computational Genomics and Data Science, created through RFA-HG-22-002. For developing skills in computational genomics and data science, these courses will leverage the resources of NIH cloud computing platforms such as NHGRIs AnVIL and the All of Us Researcher Workbench.

This grant provides funding for researchers and institutions to develop advanced imaging and biomarker technologies that improve the early detection of aggressive cancers and precancerous lesions, ultimately enhancing patient outcomes and clinical decision-making.

This funding opportunity supports innovative community-based projects aimed at reducing health disparities related to dementia and cognitive decline among underserved populations as they age.

The "Single Source for Chronic Pancreatitis Clinical Research Consortium (CPCRC) Data Coordinating Center (CPCRC-DCC)" grant aims to fund a Coordination and Data Management Center to continue and complete ongoing research on chronic pancreatitis, diabetes, and pancreatic cancer, focusing on understanding the pathophysiology, risk factors, and potential treatments, while promoting collaboration and data sharing among consortium members.

The "Service Area Competition" grant, administered by HRSA, aims to allocate approximately $244 million to up to 88 organizations to continue providing affordable, comprehensive primary health care services to underserved communities in the U.S., with a focus on vulnerable populations, from May 2025 to April 2028.

This grant provides funding to exceptional U.S.-based graduate students transitioning from predoctoral to postdoctoral research in kidney, urologic, or hematologic sciences, encouraging diverse talent to contribute to these fields.

This grant provides funding and support for underrepresented clinical scientists to develop their research skills in cancer-related fields, with a focus on addressing health disparities and preparing them for future research funding opportunities.

This funding opportunity provides financial support for early-career researchers from underrepresented backgrounds to lead independent clinical trials and develop their research skills under the mentorship of experienced scientists.

This funding opportunity provides financial support for organizations to conduct research and data analysis that improves telehealth services and access for underserved populations across the United States.

This funding opportunity provides financial support for small businesses and researchers to develop innovative products and services aimed at preventing, diagnosing, and treating Alzheimer's disease and related dementias, ultimately improving care for affected individuals and their families.

This funding opportunity provides financial support for research institutions to analyze existing national data on maternal and child health to improve health outcomes and inform policies.

This programs purpose is to support training programs that enhance and expand paraprofessionals knowledge and expertise, and to increase the number of peer support specialists and other behavioral health-related paraprofessionals who work on integrated, interprofessional teams in providing services to families impacted by OUD and other SUD. A special focus is on supporting children and adolescents in high need and high demand areas who have experienced trauma and are at risk for mental health disorders.

This funding opportunity provides $25 million to strengthen Nigeria's health systems and workforce, enabling better detection and response to public health threats at national and local levels.

This grant provides funding for researchers to study how the combined stigma of HIV and cancer affects health outcomes in HIV-positive individuals diagnosed with cancer, with a focus on developing interventions to reduce this stigma.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and test the effectiveness and implementation of family navigator models designed to promote early access, engagement and coordination of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care and monitor the trajectory of mental health symptoms and outcomes over time. Applicants are encouraged to develop and test the navigator models ability to promote early access, engagement and coordination of mental health treatment and services for children and adolescents as soon as symptoms are detected. Of interest are navigator models that coordinate needed care strategies, determine the personalized match to the level of needed service amount, frequency and intensity, and harness novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes. This FOA is published in parallel to a companion R34

This funding opportunity supports research projects that develop innovative strategies to improve HIV prevention and treatment outcomes, particularly for marginalized populations, by addressing barriers and enhancing community engagement.